Cantex secures license to develop small molecule-drug for inflammatory lung diseases
pharmaphorum
FEBRUARY 24, 2022
Clinical stage pharmaceutical company Cantex Pharmaceuticals has obtained a global licence from Harvard University’s Office of Technology Development to develop the small-molecule drug azeliragon into a treatment for inflammatory lung diseases, including COVID-19.
Let's personalize your content